Log in

Rigel Pharmaceuticals Stock Forecast, Price & News

-0.12 (-5.02 %)
(As of 09/22/2020 12:00 AM ET)
Today's Range
Now: $2.27
50-Day Range
MA: $2.44
52-Week Range
Now: $2.27
Volume2.82 million shs
Average Volume3.96 million shs
Market Capitalization$383.47 million
P/E RatioN/A
Dividend YieldN/A
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Its clinical programs also comprise R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program, which is in Phase I clinical study for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is based in South San Francisco, California.
Read More
Rigel Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RIGL



Sales & Book Value

Annual Sales$59.29 million
Book Value$0.32 per share


Net Income$-66,890,000.00


Market Cap$383.47 million
Next Earnings Date11/3/2020 (Estimated)
-0.12 (-5.02 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

How has Rigel Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Rigel Pharmaceuticals' stock was trading at $1.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RIGL shares have increased by 25.4% and is now trading at $2.27.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Rigel Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Rigel Pharmaceuticals

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Rigel Pharmaceuticals

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its quarterly earnings data on Tuesday, August, 4th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.03. The biotechnology company earned $16.02 million during the quarter, compared to the consensus estimate of $14.28 million. Rigel Pharmaceuticals had a negative net margin of 23.16% and a negative return on equity of 37.85%. During the same period last year, the company posted ($0.12) EPS.
View Rigel Pharmaceuticals' earnings history

What price target have analysts set for RIGL?

5 Wall Street analysts have issued 1 year price objectives for Rigel Pharmaceuticals' stock. Their forecasts range from $6.00 to $8.00. On average, they expect Rigel Pharmaceuticals' share price to reach $7.50 in the next twelve months. This suggests a possible upside of 230.4% from the stock's current price.
View analysts' price targets for Rigel Pharmaceuticals

Who are some of Rigel Pharmaceuticals' key competitors?

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), AEterna Zentaris (AEZS), OrganiGram (OGI), Novan (NOVN), Pennsylvania R.E.I.T. (PEI), Sorrento Therapeutics (SRNE), KushCo (KSHB) and BioNano Genomics (BNGO).

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the following people:
  • Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 58)
  • Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 54)
  • Dr. Anne-Marie S. Duliege, Exec. VP & Chief Medical Officer (Age 60)
  • Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 58)
  • Dr. Thomas A. Raffin, Co-Founder (Age 72)

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (12.71%), Hudson Bay Capital Management LP (1.96%), Candriam Luxembourg S.C.A. (1.15%), Macquarie Group Ltd. (0.95%), Jacobs Levy Equity Management Inc. (0.83%) and Two Sigma Advisers LP (0.51%). Company insiders that own Rigel Pharmaceuticals stock include Dean L Schorno and Nelson Cabatuan.
View institutional ownership trends for Rigel Pharmaceuticals

Which major investors are selling Rigel Pharmaceuticals stock?

RIGL stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Sofinnova Investments Inc., FMR LLC, Candriam Luxembourg S.C.A., Hudson Bay Capital Management LP, Worth Venture Partners LLC, Alps Advisors Inc., and UBS Group AG.
View insider buying and selling activity for Rigel Pharmaceuticals

Which major investors are buying Rigel Pharmaceuticals stock?

RIGL stock was acquired by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Jacobs Levy Equity Management Inc., Assenagon Asset Management S.A., Russell Investments Group Ltd., Nuveen Asset Management LLC, Dupont Capital Management Corp, Principal Financial Group Inc., and Principal Financial Group Inc..
View insider buying and selling activity for Rigel Pharmaceuticals

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $2.27.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $383.47 million and generates $59.29 million in revenue each year. The biotechnology company earns $-66,890,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Rigel Pharmaceuticals employs 158 workers across the globe.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is www.rigel.com.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.